Stable anti-cd79b immunoconjugate formulations
AssigneeGenentech, Inc.
InventorsAnkit R. PATEL, Jun LIU
Life of this patent
Estimating the term…
Abstract
The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
Claims110
A pharmaceutical composition comprising an anti-CD79b immunoconjugate and a surfactant, wherein the surfactant is at a concentration of at least 0.06% w/v, and wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO:
- 1);
- (b) an HVR-L2 sequence of AASNLES (SEQ ID NO:
- 2);
- and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO:
- 3);
- wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO:
- 4);
- (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO:
- 5);
- and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO:
- 6);
- Val is valine;
- Cit is citrulline;
- and
- p is a value from about 1 to about 8.
The pharmaceutical composition of claim 22, wherein the sucrose is at a concentration of 120 mM.
A pharmaceutical composition produced by lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO:
- 1);
- (b) an HVR-L2 sequence of AASNLES (SEQ ID NO:
- 2);
- and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO:
- 3);
- wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO:
- 4);
- (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO:
- 5);
- and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO:
- 6);
- Val is valine;
- Cit is citrulline;
- and
- p is a value from about 1 to about 8.
A pharmaceutical composition produced by lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:
- 9, the light chain comprises the amino acid sequence of SEQ ID NO:
- 10;
- Val is valine;
- Cit is citrulline;
- and p is a value from about 2 to about 5.
A pharmaceutical composition produced by a process comprising the steps of:
- (a) lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:
- 9, the light chain comprises the amino acid sequence of SEQ ID NO:
- 10;
- Val is valine;
- Cit is citrulline;
- and p is a value from about 2 to about 5, to produce a lyophilized composition;
- (b) reconstituting the lyophilized composition with about 7.2 ml sterile water for injection (SWFI) to produce a reconstituted composition;
- and
- (c) diluting the reconstituted composition into an isotonic buffer in an intravenous (IV) bag to produce the pharmaceutical composition,
- wherein the final volume of the pharmaceutical composition in the IV bag is about 100 ml, and
- wherein the final concentration of the immunoconjugate in the pharmaceutical composition is about 0.72 mg/ml or about 2.7 mg/ml.
A liquid composition comprising a) between about 0.72-2.7 mg/ml polatuzumab vedotin;
- b) between about 0.36-0 1.35 mM sodium succinate;
- c) between about 0.51-16.24 mM sucrose;
- d) between about 0.0432-0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5 and about 5.7.
A liquid composition comprising a) about 0.72 mg/ml polatuzumab vedotin;
- b) about 0.36 mM sodium succinate;
- c) about 0.51 mM sucrose;
- d) about 0.0432 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5.1 and about 5.4.
A liquid composition comprising a) about 2.7 mg/ml polatuzumab vedotin;
- b) about 0 1.35 mM sodium succinate;
- c) about 16.24 mM sucrose;
- d) about 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5.1 and about 5.4.
A pharmaceutical composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the pharmaceutical composition, when reconstituted in water, forms a liquid pharmaceutical composition comprising the anti-CD79b immunoconjugate at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant at a concentration of at least 0.06% w/v, the succinate buffer at a concentration of about 10 mM to about 200 mM, and the sugar at a concentration of about 100 mM to about 260 mM, wherein the liquid pharmaceutical composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO:
- 1);
- (b) an HVR-L2 sequence of AASNLES (SEQ ID NO:
- 2);
- and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO:
- 3);
- wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO:
- 4);
- (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO:
- 5);
- and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO:
- 6);
- Val is valine;
- Cit is citrulline;
- and
- p is a value from about 1 to about 8.
A liquid composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant is at a concentration of at least 0.06% w/v, the succinate buffer is at a concentration of about 10 mM to about 200 mM, and the sugar is at a concentration of about 100 mM to about 260 mM, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO:
- 1);
- (b) an HVR-L2 sequence of AASNLES (SEQ ID NO:
- 2);
- and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO:
- 3);
- wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO:
- 4);
- (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO:
- 5);
- and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO:
- 6);
- Val is valine;
- Cit is citrulline;
- and
- p is a value from about 1 to about 8.
A lyophilized pharmaceutical composition comprising about 150 mg of an anti-CD79b immunoconjugate, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO:
- 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO:
- 10;
- Val is valine;
- Cit is citrulline;
- and
- p is a value from about 2 to about 5.
A lyophilized pharmaceutical composition comprising about 150 mg of polatuzumab vedotin, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose.
A lyophilized pharmaceutical composition comprising about 140 mg of an anti-CD79b immunoconjugate, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO:
- 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO:
- 10;
- Val is valine;
- Cit is citrulline;
- and
- p is a value from about 2 to about 5.
A lyophilized pharmaceutical composition comprising about 140 mg of polatuzumab vedotin, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose.
A lyophilized pharmaceutical composition comprising about 30 mg of an anti-CD79b immunoconjugate, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:
- wherein:
- Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO:
- 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO:
- 10;
- Val is valine;
- Cit is citrulline;
- and p is a value from about 2 to about 5.
A lyophilized pharmaceutical composition comprising about 30 mg of polatuzumab vedotin, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose.
A lyophilized pharmaceutical composition comprising about 140-150 mg of polatuzumab vedotin, about 8.4-9.0 mg polysorbate 20, about 8.27-8.88 mg succinic acid, about 3.80-4.08 mg sodium hydroxide, and about 288-309 mg sucrose.
A liquid pharmaceutical composition comprising a) 5-60 mg/ml polatuzumab vedotin;
- b) 10-200 mM sodium succinate;
- c) 100-260 mM sucrose;
- d) 0.06-0.12% w/v polysorbate 20, wherein the pH of the liquid composition is between 5 and 6.
A liquid pharmaceutical composition comprising a) 20 mg/ml polatuzumab vedotin;
- b) 10 mM sodium succinate;
- c) 120 mM sucrose;
- d) 0.12% w/v polysorbate 20, wherein the pH of the liquid composition is about 5.3.
A method of treating a proliferative disorder in a patient in need thereof comprising administering to the patient the pharmaceutical composition or the liquid composition of any one of the preceding claims.
Dependencies are inferred from the claim text.